Pharos iBio Co., Ltd. (KOSDAQ:388870)

South Korea flag South Korea · Delayed Price · Currency is KRW
8,510.00
-160.00 (-1.85%)
At close: Feb 13, 2026
Market Cap110.17B +4.5%
Revenue (ttm)n/a
Net Income-9.82B
EPS-759.07
Shares Out12.95M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume85,182
Average Volume225,152
Open8,700.00
Previous Close8,670.00
Day's Range8,470.00 - 8,800.00
52-Week Range4,630.00 - 12,120.00
Beta-0.10
RSI37.64
Earnings DateMar 17, 2026

About Pharos iBio

Pharos iBio Co., Ltd. engages in the development of treatments for rare and refractory diseases using AI based drug development platform in South Korea. It develops PHI-101-AML that is in phase 1 clinical trial for the treatment of refractory/recurrent acute myelogenous leukemia (AML); PHI-101-OC that is in phase 1 clinical trial for the treatment of recurrent ovarian cancer; PHI-501 for refractory solid cancer; PHI-301 for the treatment of refractory lung cancer; and PHI-601 for the treatment of menin inhibitor. The company was founded in 2016... [Read more]

Industry Pharmaceutical Preparations
Founded 2016
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 388870
Full Company Profile

Financial Performance

Financial Statements